Key statistics
On Thursday, MannKind Corp (MNKD:NMQ) closed at 6.90, -9.57% below its 52-week high of 7.63, set on Nov 06, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.89 |
---|---|
High | 6.98 |
Low | 6.74 |
Bid | 6.90 |
Offer | 7.23 |
Previous close | 6.88 |
Average volume | 3.20m |
---|---|
Shares outstanding | 275.78m |
Free float | 270.74m |
P/E (TTM) | 97.02 |
Market cap | 1.90bn USD |
EPS (TTM) | 0.0711 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
- MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update
- MannKind to Present at 2024 UBS Healthcare Conference
- MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
- MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
- More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®)
- MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
- MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference
- MannKind to Present at Upcoming Conferences
- Kent Kresa to Retire from MannKind’s Board of Directors; Steven B. Binder to be Appointed to the Board
- MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update
More ▼